Wave Life Sciences
WVE
Performance
About Wave Life Sciences
Wave Life Sciences is a biotechnology company focused on developing RNA-targeting therapeutics to treat rare and common diseases. Their research leverages a toolkit of RNA medicines and chemistry innovation, with programs spanning conditions such as Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, and obesity. The company emphasizes science-driven discovery through its PRISM platform to advance first- or best-in-class medicines aimed at improving human health. Headquartered in the United States, Wave Life Sciences collaborates with researchers and patients to translate genetic insights into transformative therapies.
Recent News
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
GSK Returns Rights to Wave's RNA Editing Program for AATD
JPM26: Korro Bio Looks To Save Itself Despite Unenviable Position
Deep Dive: Huntington’s at a Crossroads
Obesity Data, Kymera and FDA Sentiment Survey Results — a BioCentury Podcast
Wave To Work Alone on RNA Editor as AATD Picture Becomes Clearer
Arrowhead Enters Obesity Chat by Doubling Tirzepatide’s Weight Loss in Combo Study
8 Healthcare Stocks Insiders Are Buying
GSK Hands RNA Editor Back to Wave After Underwhelming Early AATD Data
